Aiphagan addition to prostaglandin analogue(PG) and/or beta-blocker and/or carbonic anhydrase inhibitor in normal pressure glaucoma study

Aiphagan addition to prostaglandin analogue(PG) and/or beta-blocker and/or carbonic anhydrase inhibitor in normal pressure glaucoma study - AABC study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012582

Enrollment

Registered

2013-12-15

Start date

2012-05-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Normal tension glaucoma

Interventions

Added to 0.1% brimonidine tartrate ophthalmic solution for 3 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients under treatment with prostagrandine and/or beta blockers who are judged to require the addition of Brimonidine with be not able to achieve target IOP as on their current IOP lowering monotherapy. 2.On treatment IOPs of bilateral eyes were between 13 and 16 mmHg in at least three consecutive measurements without changing the prescription for three months or more; patients with an IOP of 10 to 12 mmHg were eligible if the central corneal thickness (CCT) was 470 micro meter or less. 3.Visual aquity is equall or more 0.5 4. Correction is under -10 diopter.

Exclusion criteria

Exclusion criteria: 1.Complications with chronic or recurrent uveitis,scleritis,or corneal herpes. 2.History of ocular trauma or intraocular conventional surgery or laser ocular surgery in the study eye within 3 months before baseline examinations. 3.Any abnormality preventing reliable applanation tonometer in the study eye. 4.Known medical history of allergic to PGAs or beta-blockers. 5.Contraindication of betablockers. 6.Patients using an IOP-lowering drug other than those to be used in the study. 7.Patients using systemic administration of an oral CAI (Diamox,etc.). 8.Patient having serious eyes complications. 9.Women who are pregnant or lactating. 10.Severe dementia 11.Patients who are judged to be inappropriate for participation in the study for other reason by the doctor in charge.

Design outcomes

Primary

Measure	Time frame
Efficacy IOP value;IOP-lowering effect from baseline (reduced value;reduction rate%)	—

Secondary

Measure	Time frame
Safety 1.Ocular safety assessment: Conjunctival hyperemia,adverse events 2.Systemic safety assessment: Blood pressure,the pulse,adverse events	—

Countries

Japan

Contacts

Public ContactToyoaki Tsumura

Fussa Hospital Ophthalmology

tsumura@fussahsp.jp042-551-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026